390 related articles for article (PubMed ID: 21172025)
1. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.
Cittelly DM; Das PM; Salvo VA; Fonseca JP; Burow ME; Jones FE
Carcinogenesis; 2010 Dec; 31(12):2049-57. PubMed ID: 20876285
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
Huynh FC; Jones FE
PLoS One; 2014; 9(12):e114419. PubMed ID: 25532106
[TBL] [Abstract][Full Text] [Related]
4. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.
Zhao JJ; Lin J; Yang H; Kong W; He L; Ma X; Coppola D; Cheng JQ
J Biol Chem; 2008 Nov; 283(45):31079-86. PubMed ID: 18790736
[TBL] [Abstract][Full Text] [Related]
6. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
7. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
8. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
Ahmad A; Ginnebaugh KR; Yin S; Bollig-Fischer A; Reddy KB; Sarkar FH
BMC Cancer; 2015 Jul; 15():540. PubMed ID: 26206152
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.
Miller TE; Ghoshal K; Ramaswamy B; Roy S; Datta J; Shapiro CL; Jacob S; Majumder S
J Biol Chem; 2008 Oct; 283(44):29897-903. PubMed ID: 18708351
[TBL] [Abstract][Full Text] [Related]
10. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
11. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
Li XN; Liu AH; Tang X; Ren Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
[TBL] [Abstract][Full Text] [Related]
12. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
[TBL] [Abstract][Full Text] [Related]
13. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
Ren YQ; Wang HJ; Zhang YQ; Liu YB
Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
15. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
[TBL] [Abstract][Full Text] [Related]
16. miRNA-128 and miRNA-223 regulate cholesterol-mediated drug resistance in breast cancer.
Palma GBH; Kaur M
IUBMB Life; 2023 Sep; 75(9):743-764. PubMed ID: 37070323
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
18. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
19. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
Han X; Li Q; Liu C; Wang C; Li Y
J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
Li X; Wu Y; Liu A; Tang X
Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
